Review Note

Last Update: 12/13/2024 04:42 AM

Current Deck: AnkPath::dermatopathology::Zanki Dermatology

Published

Currently Published Content

Text

Metastatic or unresectable melanoma in patients with BRAF {{c1::V600E::AAs}} mutations may benefit from {{c2::vemurafenib}}, a BRAF kinase inhibitor

Extra

Lecture Notes

Missed Questions

Pathoma

Boards and Beyond

First Aid

Sketchy

Watch Malignant Melanoma

Sketchy 2

Sketchy Extra

Picmonic

Pixorize

Physeo

Bootcamp

Watch associated Bootcamp video

OME

Additional Resources

Atlas:

One by one

Current Tags:

#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Dermatology #AK_Step1_v11::#B&B::07_Derm::10_Skin_Cancer #AK_Step1_v11::#Bootcamp::Dermatology::Malignant_Skin_Disorders::Melanoma

Pending Suggestions

No pending suggestions for this note.